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     The effect of bovine serum albumin (BSA) on drug absorption from the liver surface in 
rats was examined by using three organic anions (phenol red, bromphenol blue and 
bromosulphonphthalein) as model drugs which have a high affinity for albumin.   The 
binding ratio of the model drugs (3 mg/ml in phosphate buffer) to BSA varied widely at a 
BSA concentration of 0.1 - 10 % (W/V).   The model drugs (3 mg/ml X 0.1 ml) with or 
without BSA were applied to the rat liver surface in vivo employing a cylindrical glass cell 
(i.d. 9 mm, area 0.64 cm2).   The absorption ratios of the model drugs from the rat liver 
surface at 6 h, calculated from the amount recovered from the glass cell, decreased with an 
increase in BSA concentration.   A similar trend was observed with biliary recovery of the 
model drugs.   A marked reduction in the absorption ratio was seen with 
bromosulphonphthalein, which has the highest binding activity to BSA among the three 
organic anions.   Accordingly, protein binding appears to be a significant factor with respect 
to drug absorption from the liver surface. 
 
     Key words   protein binding; absorption; liver surface; rat; organic anion; bovine 
serum albumin 
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     Previously,1) we reported the possibility of drug absorption from the liver surface in rats 
and demonstrated that direct application to the liver surface can be useful for drug targeting to 
the desired site in the liver.   Furthermore, we suggested that a specialized transport process 
might not exist for drug absorption from the rat liver surface.2) 
     Protein binding is one of the most important factors in determining drug disposition in 
the body, and it is assumed that the unbound fraction is involved mainly in the drug transport.   
The serous fluid in the peritoneal cavity has a total protein concentration of ca. 2 % (W/V), 
and it is well known that albumin concentration changes extensively in serious disease.   
Accordingly, the effect of protein binding on drug absorption from the liver surface needs to 
be elucidated in order to attain effective and safe drug delivery.   Although there have been 
some reports concerning the intraperitoneal transport of proteins,3-5) the absorption 
characteristics of protein from a specific organ remains to be clarified. 
     In a series of investigations on elucidation of the absorption mechanism from the liver 
surface, we examined the effect of bovine serum albumin (BSA) on drug absorption from the 
liver surface in rats.   In the present study, phenol red (PR), bromphenol blue (BPB) and 
bromosulphonphthalein (BSP) were selected as model drugs with a relatively high affinity for 
BSA, because their in vivo absorbability from the rat liver surface had been previously 
determined.1,2) 
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MATERIALS AND METHODS 
 
     Chemicals   PR and BPB were purchased from Nacalai Tesque, Inc. (Kyoto, Japan).   
BSA (fraction V) and BSP were obtained from Sigma Chemical Co. (St. Louis, MO, U.S.A.).   
All other chemicals were reagent grade products. 
     Determination of Binding Ratio of the Model Drugs to BSA   The binding of the 
model drugs to BSA in an isotonic phosphate buffer (pH 7.4) at 37°C was studied with the 
chamber cells for equilibrium dialysis by the method of Takada et al.6) after slight 
modification.   The two chambers were separated into donor and receiver sides using a 
Visking tube membrane (Mw cutoff, 12000 - 14000).   BSA was dissolved in the buffer 
solution to give a concentration of 0.2 mM.   The drug concentrations varied from 0.01 to 
10 mM.   Three ml of the mixture of the model drug and BSA and the buffer solution were 
added to the donor and receiver sides, respectively.   After dialysis at 37°C for 72 h, the 
solutions in the donor and receiver sides were removed, then the concentrations of unbound 
and bound model drug were measured.   Adsorption of the model drugs onto the dialysis 
membrane surface was negligible. 
     In Vivo Experiment   All animal procedures in the present study conformed to the 
Guidelines for Animal Experimentation in Nagasaki University. 
     Male Wistar rats (230-250 g) were anesthetized with sodium pentobarbital (50 mg/kg, 
i.p.) and the left femoral artery was cannulated with a polyethylene tube (i.d. 0.5 mm, o.d. 0.8 
mm; Dural Plastics, Dural, Australia).   After the middle abdomen was cut open about 3 cm, 
the common bile duct was cannulated with a polyethylene tube (i.d. 0.28 mm, o.d. 0.61 mm; 
Becton Dickinson & Co., Parsippany, NJ, U.S.A.).   A cylindrical glass cell (i.d. 9 mm, area 
0.64 cm2) was attached to the rat liver surface at the area of the left lobe with Aron Alpha 
(Sankyo Co., Ltd, Tokyo, Japan).   The body temperature of the rats was kept at 37°C by a 
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heat lamp during the experiment.   The test solution was prepared in an isotonic phosphate 
buffer (pH 7.4) to yield a drug concentration of 0.3 mg/0.1 ml containing 0, 0.1, 1, 5 and 10 % 
(W/V) BSA, and added to the glass cell directly.   The top of the glass cell was sealed with a 
piece of aluminum foil to prevent evaporation of the applied solution.   Blood samples (200 
µl) were collected at selected times after dosing from the heparinized cannula inserted into the 
femoral artery over a 6-h period, and were centrifuged at 15,000 rpm for 5 min.   Bile 
samples were collected at appropriate time intervals for 6 h.   At 6 h after the application, 
urine was collected directly from the bladder with a syringe, and the solution remaining in the 
glass cell was withdrawn by more than five washings with saline. 
     Analytical Method   The concentrations of the model drugs in the plasma, bile, urine 
and remaining solution in the glass cell were determined as follows. 
     PR: The concentration of free PR was determined spectrophotometrically at 560 nm 
after dilution with 1 N NaOH solution.   The total concentration of free PR and its 
metabolite was measured in the same manner after they were subjected to acid hydrolysis (1 
N HCl at 100°C for 30 min).7) 
     BPB: The concentration of BPB was determined spectrophotometrically at 591 nm after 
dilution with an isotonic phosphate buffer (pH 7.4).6) 
     BSP: The total concentration of free BSP and its metabolite was determined 
spectrophotometrically at 580 nm after dilution with 0.1 N NaOH solution.8) 
     Statistical Analysis   Statistical analysis was performed by applying the unpaired 
Student’s t-test.   p < 0.05 was considered to be statistically significant from the control.   




     In Vitro Binding of the Model Drugs to BSA   Figure 1 illustrates the Scatchard 
plots for in vitro binding data of the model drugs in an isotonic phosphate buffer (pH 7.4).   
In Fig. 1, r is the bound molar ratio of the model drugs (r = [Db] / [Pt]), where [Db] and [Pt] are 
the molar concentration of bound drug and BSA, respectively, and [Du] is the molar 
concentration of the unbound drug.  Since Fig. 1 was close to the two-phase patterns for 
each model drug, the Scatchard plot can be explained as follows, 

















where K (K1, K2) and n (n1, n2) are the association constant and number of binding sites for 
each site, respectively. 
     The best fit of Eq. (1) was obtained by using the non-linear regression program 
MULTI9) (Fig. 1), based on the assumption of two types of binding sites with different 
affinities and capacities.   As shown in Table 1, the binding parameters for the model drugs 
differed greatly.   The extent of BSP binding to BSA was the highest among the three model 
drugs.   The bound fraction (%) in the presence of 0.1, 1, 5 and 10 % (W/V) BSA was also 
estimated from these parameters (Table 1).   The binding ratio of the model drugs to BSA 
increased according to BSA concentration.   In particular, more than 90 % of BSP and BPB 
existed in the bound form above 5 % BSA. 
     Effect of BSA on the Appearance of Model Drugs in the Plasma and Bile after 
Application to the Rat Liver Surface   PR was found in the plasma after its application to 
the rat liver surface in the presence or absence of BSA in the drug solution (Fig. 2).   For 
BPB and BSP, their plasma concentrations were below the limit of detection (0.087 µg/ml for 
BPB; 0.10 µg/ml for BSP), probably because of rapid hepatic uptake.   The PR plasma 
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concentration decreased with an increase in the concentration of BSA for up to 6 h, 
suggesting a decreased absorption rate from the rat liver surface.   The maximum 
concentration of PR in the presence of 10 % BSA was about one-fourth of that in the control. 
     Every model drug absorbed from the rat liver surface appeared into the bile (excretion 
patterns not shown).   The biliary excretion rates of the model drugs were decreased up to 6 
h, according to the BSA concentration, similar to the plasma concentration of PR.   This 
finding might be due to the suppression of the absorption rate of the model drugs from the rat 
liver surface. 
     Recovery of the Model Drugs in the Bile, Urine and Solution Remaining in the 
Glass Cell   Table 2 summarizes the recovery of the model drugs in the bile, urine and 
solution remaining in the glass cell after application to the rat liver surface in the presence or 
absence of BSA.   The absorption ratio of the model drugs at 6 h, calculated from the 
amount remaining in the glass cell, decreased considerably, with an increase in the BSA 
concentration.   In the presence of 10 % BSA, the absorption ratio at 6 h for PR, BPB and 
BSP was 38, 22 and 10 % of the control, respectively.   This order closely correlated with 
the tightness of their binding to BSA. 
     PR was excreted into the bile and urine, whereas BPB and BSP were predominantly 
excreted in the bile.   The urinary recovery of PR and the biliary recovery of the model 
drugs were decreased in proportion to the decrease in the absorption ratio (Table 2).   A 
marked reduction was observed with the biliary recovery of BPB and BSP at a BSA 




     In the present study, protein binding was found to be an important factor in controlling 
the drug absorption from the liver surface.   The decreased absorption rate of the model 
drugs in the presence of BSA might be associated with an apparent increase in molecular 
weight according to protein binding.   Accordingly, the absorbability of a drug with high 
protein binding activity or a macromolecular drug such as bioactive peptide and protein is 
considered to be extremely low.   But, BPB and BSP were absorbed from the rat liver 
surface to some extent (18.9 and 6.6 % of dose in 6 h, respectively) in the presence of 10 % 
BSA (Table 2), although more than 99 % of them bound to BSA (Table 1). 
     The hepatic uptake of the three organic anions as models with a high affinity for BSA 
from the blood (sinusoid) space to the liver cell is assumed to be inhibited by plasma proteins 
such as albumin.   On the other hand, several investigators have reported that the hepatic 
uptake rate is not proportional to the unbound fraction, and proposed the existence of 
albumin-mediated transport.10-12)   However, the effect of albumin on the hepatic uptake of 
albumin-bound substances remains controversial, judging from the series of investigations of 
this phenomenon.13-18) 
     Previously,2) we suggested that the specific transport mechanism, such as active 
transport, might not involve the drug absorption from the rat liver surface membrane, which is 
constructed mainly of collagen and fibronectin.   It is of physiological interest that 
absorption from the rat liver surface membrane proceeds such that almost all of the drug binds 
to albumin, although the precise mechanism could not be analyzed in the present 
experimental system. 
     Consequently, we clarified that protein binding tended to suppress drug absorption 
from the rat liver surface.   The effect of molecular weight on drug absorbability from the 
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liver surface remains to be elucidated in the future. 
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Figure titles and legends 
Fig. 1.   Scatchard Plots of Binding to BSA of PR(○), BPB(△) and BSP(□) in pH 7.4 
Phosphate Buffer at 37°C 
   Inset shows the same plot of PR for the small concentration range.   Curves show the 
simulated functions obtained based on the binding parameters shown in Table 1. 
Fig. 2.   Plasma Concentration Profiles of PR after Application to Rat Liver Surface at a 
Dose of 0.3 mg in the Presence or Absence of BSA 
   BSA concentration is 0 (●), 0.1 (△), 1 (○), 5 (◇) and 10 % (□).   The result of 
the control (without BSA) was reported previously.2)   Each point represents the mean ± S.E. 




Table 1.   Binding Parameters and Binding Ratio to BSA of PR, BPB and BSP 
(3 mg/ml) in pH 7.4 Phosphate Buffer at 37°C 
 
   Binding parameters     Binding ratio (%)   
  K1  n1 K2  n2 + BSA (%) 
  (mM-1) (mM-1)  0.1 1 5 10 
 
 PR 34.6 1.4 0.4 8.8 1.5 14.3 59.0 83.3 
 
 BPB 158.5 3.6 0.3 14.8 4.0 35.4 90.0 99.5 
 




Table 2.   Recovery (% of dose) of PR, BPB and BSP after Application to Rat Liver 
Surface at a Dose of 0.3 mg in the Presence or Absence of BSA 
 
 + BSA   PR     BPB     BSP   
 (%) Glass cell Bile Urine Glass cell Bile Glass cell Bile 
 
  Control 8.9a) 47.4a) 38.7a) 14.3 69.1 34.3 60.9 
  ±2.1 ±4.4 ±6.5 ±1.1 ±1.7 ±2.7 ±3.6 
 
 0.1 11.3 47.0 34.0 16.8 72.9 41.0 56.9 
  ±1.4 ±7.1 ±9.0 ±0.1 ±2.3 ±1.3 ±4.3 
 
 1 25.2** 36.0 31.9 32.0** 50.2** 62.8** 40.1** 
  ±1.8 ±2.1 ±2.4 ±2.1 ±2.5 ±0.9 ±3.1 
 
 5 35.1** 27.7** 22.2 72.2** 14.3** 84.5** 12.4** 
  ±2.8 ±3.0 ±6.2 ±0.6 ±2.2 ±3.8 ±1.9 
 
 10 65.5** 16.7** 15.6* 81.1** 10.0** 93.4** 12.4** 
  ±1.4 ±1.1 ±3.5 ±0.4 ±1.4 ±0.8 ±0.4 
 
 
Each value is the mean ± S.E. of at least four experiments.   a) Results were 
reported previously.2)   Statistical significance from control (*p < 0.05, ** p < 0.01). 
 
